Logotipo del repositorio
Logotipo del repositorio
 

Caracterización clínico-patológica de pacientes con nefropatía por IgA empleando la escala de Oxford atendidos en una clínica de IV nivel en Barranquilla – Colombia

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_f1cf
dc.contributor.advisorCastillo Parodi, Luis
dc.contributor.advisorGuido Musso, Carlos
dc.contributor.authorDíaz Orozco, Luis Rafael
dc.date.accessioned2025-02-06T14:24:54Z
dc.date.available2025-02-06T14:24:54Z
dc.date.issued2025
dc.description.abstractIntroducción: La nefropatía por IgA es la glomerulopatía primaria más frecuente a nivel mundial y una causa relevante de enfermedad renal crónica. Su presentación clínica y evolución son variables, dependiendo de múltiples factores clínicos, histológicos y demográficos. Este estudio se llevó a cabo en una clínica de cuarto nivel en Barranquilla, Colombia, con el propósito de analizar las características epidemiológicas, clínicas e histológicas de los pacientes diagnosticados con nefropatía por IgA, así como evaluar la correlación entre estos factores y el riesgo de progresión a insuficiencia renal. Objetivo: Caracterizar los antecedentes médicos, la sintomatología clínica, los parámetros histológicos y las correlaciones entre estos factores en pacientes con nefropatía por IgA, con el fin de determinar su impacto en la progresión de la enfermedad y la función renal. Metodología: Se incluyeron 36 pacientes diagnosticados con nefropatía por IgA mediante biopsia renal. Se recolectaron datos sobre edad, género, procedencia geográfica, antecedentes médicos y uso de fármacos, además de variables clínicas como la tasa de filtración glomerular (TFG), la proteinuria, la presencia de hematuria y la necesidad de diálisis. Se analizaron los parámetros histológicos de acuerdo con la escala Oxford, evaluando la proliferación mesangial, el daño epitelial, la esclerosis glomerular y la presencia de depósitos inmunes. Se realizaron análisis estadísticos para establecer correlaciones entre los hallazgos clínicos e histológicos, incluyendo la prueba de Chi-cuadrado y la correlación de Pearson.spa
dc.description.abstractIntroduction: IgA nephropathy is the most common primary glomerulopathy worldwide and a significant cause of chronic kidney disease. Its clinical presentation and progression vary depending on multiple clinical, histological, and demographic factors. This study was conducted at a quaternary nephrology clinic in Barranquilla, Colombia, to analyze the epidemiological, clinical, and histological characteristics of patients diagnosed with IgA nephropathy and evaluate the correlation between these factors and the risk of progression to renal failure. Objective: To characterize medical history, clinical symptoms, histological parameters, and correlations between these factors in patients with IgA nephropathy to determine their impact on disease progression and renal function. Methodology: A total of 36 biopsy confirmed IgA nephropathy patients were included. Data on age, gender, geographic origin, medical history, and medication use were collected, along with clinical variables such as glomerular filtration rate (GFR), proteinuria, hematuria, and dialysis requirement. Histological parameters were assessed using the Oxford classification, evaluating mesangial proliferation, epithelial injury, glomerular sclerosis, and immune deposits. Statistical analyses, including Chi-square and Pearson correlation tests, were conducted to establish associations between clinical and histological findings.eng
dc.format.mimetypepdf
dc.identifier.urihttps://hdl.handle.net/20.500.12442/16223
dc.language.isospa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Stateseng
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.subjectNefropatía por IgAspa
dc.subjectTasa de filtrado glomerularspa
dc.subjectProteinuriaspa
dc.subjectInsuficiencia renal crónicaspa
dc.subject.keywordsIgA Nephropathyeng
dc.subject.keywordsGlomerular filtration rateeng
dc.subject.keywordsRenal Insufficiency chroniceng
dc.titleCaracterización clínico-patológica de pacientes con nefropatía por IgA empleando la escala de Oxford atendidos en una clínica de IV nivel en Barranquilla – Colombiaspa
dc.type.driverinfo:eu-repo/semantics/other
dc.type.spaOtros
dcterms.referencesRajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American Journal of the Medical Sciences 2021;361:176–94. https://doi.org/10.1016/j.amjms.2020.10.003.eng
dcterms.referencesSchena FP, Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology 2018;38:435–42. https://doi.org/10.1016/j.semnephrol.2018.05.013.eng
dcterms.referencesWyatt RJ, Julian BA. IgA Nephropathy. N Engl J Med 2013;368:2402–14. https://doi.org/10.1056/NEJMra1206793.eng
dcterms.referencesCoppo R. IgA Nephropathy: A European Perspective in the Corticosteroid Treatment. Kidney Dis 2018;4:58–64. https://doi.org/10.1159/000487265.eng
dcterms.referencesCanetta PA, Kiryluk K, Appel GB. Glomerular Diseases: Emerging Tests and Therapies for IgA Nephropathy. Clinical Journal of the American Society of Nephrology 2014;9:617–25. https://doi.org/10.2215/CJN.07260713.eng
dcterms.referencesO’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrology Dialysis Transplantation 2018;33:661–9. https://doi.org/10.1093/ndt/gfx189.eng
dcterms.referencesMcQuarrie EP, Mackinnon B, Young B, Yeoman L, Stewart G, Fleming S, et al. Centre variation in incidence, indication and diagnosis of adult native renal biopsy in Scotland. Nephrology Dialysis Transplantation 2009;24:1524–8. https://doi.org/10.1093/ndt/gfn677.eng
dcterms.referencesLai KN, Leung JCK, Tang SCW. Recent advances in the understanding and management of IgA nephropathy. F1000Res 2016;5:161. https://doi.org/10.12688/f1000research.7352.1.eng
dcterms.referencesLococo B, Alberton V, Fazzini B, Smuclir Quevedo A, Morales D, Malvar A. Nefropatía por IgA. Revisión y conducta terapéutica a propósito de un caso clínico. Rev Nefrol Dial Traspl. 2016 ;36(2):108-23. Disponible en: http://www.revistarenal.org.ar/index.php/rndt/article/view/66spa
dcterms.referencesBarbour SJ, Reich HN. Risk Stratification of Patients With IgA Nephropathy. American Journal of Kidney Diseases 2012;59:865–73. https://doi.org/10.1053/j.ajkd.2012.02.326.eng
dcterms.referencesBarbour SJ, Coppo R, Zhang H, Liu Z-H, Suzuki Y, Matsuzaki K, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med 2019;179:942. https://doi.org/10.1001/jamainternmed.2019.0600.eng
dcterms.referencesFloege J, Amann K. Primary glomerulonephritides. The Lancet 2016;387:2036–48. https://doi.org/10.1016/S0140-6736(16)00272-5.eng
dcterms.referencesBarbour S, Reich H. An update on predicting renal progression in IgA nephropathy: Current Opinion in Nephrology and Hypertension 2018;27:214–20. https://doi.org/10.1097/MNH.0000000000000405.eng
dcterms.referencesLee H, Kim DK, Oh K-H, Joo KW, Kim YS, Chae D-W, et al. Mortality and Renal Outcome of Primary Glomerulonephritis in Korea: Observation in 1,943 Biopsied Cases. Am J Nephrol 2013;37:74–83. https://doi.org/10.1159/000345960.eng
dcterms.referencesGarcía Herrera HG, Restrepo Valencia CA, Buitrago Villa CA. Características clínicas e histológicas de las enfermedades parenquimatosas renales en una muestra de biopsias renales obtenidas entre el año 2002 y el 2017 en el departamento de Caldas, Colombia. Rev Colomb Nefrol 2018;5:107. https://doi.org/10.22265/acnef.0.0.300.spa
dcterms.referencesIsmail M, Lakouz K, Abdelbary E. Clinicopathological correlations of renal pathology: A single center experience. Saudi J Kidney Dis Transpl 2016;27:557. https://doi.org/10.4103/1319-2442.182399.eng
dcterms.referencesMagistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney International 2015;88:974–89. https://doi.org/10.1038/ki.2015.252.eng
dcterms.referencesKiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch–Schönlein purpura nephritis. Kidney International 2011;80:79–87. https://doi.org/10.1038/ki.2011.16.eng
dcterms.referencesGharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, et al. Aberrant IgA1 Glycosylation Is Inherited in Familial and Sporadic IgA Nephropathy. Journal of the American Society of Nephrology 2008;19:1008–14. https://doi.org/10.1681/ASN.2007091052.eng
dcterms.referencesKnoppova B, Reily C, Maillard N, Rizk DV, Moldoveanu Z, Mestecky J, et al. The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Front Immunol 2016;7. https://doi.org/10.3389/fimmu.2016.00117.eng
dcterms.referencesLamm ME, Emancipator SN, Robinson JK, Yamashita M, Fujioka H, Qiu J, et al. Microbial IgA Protease Removes IgA Immune Complexes from Mouse Glomeruli In Vivo: Potential Therapy for IgA Nephropathy. The American Journal of Pathology 2008;172:31–6. https://doi.org/10.2353/ajpath.2008.070131.eng
dcterms.referencesKnoppova B, Reily C, King RG, Julian BA, Novak J, Green TJ. Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment. JCM 2021;10:4501. https://doi.org/10.3390/jcm10194501.eng
dcterms.referencesYamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, et al. Cigarette Smoking and Progression of IgA Nephropathy. American Journal of Kidney Diseases 2010;56:313–24. https://doi.org/10.1053/j.ajkd.2010.02.351.eng
dcterms.referencesKataoka H, Ohara M, Honda K, Mochizuki T, Nitta K. Maximal glomerular diameter as a 10-year prognostic indicator for IgA nephropathy. Nephrology Dialysis Transplantation 2011;26:3937–43. https://doi.org/10.1093/ndt/gfr139.eng
dcterms.referencesSchiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway. Science 2001;293:2111–4. https://doi.org/10.1126/science.1061964.eng
dcterms.referencesMcCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, et al. Mice overexpressing BAFF develop a commensal flora–dependent, IgA-associated nephropathy. J Clin Invest 2011;121:3991–4002. https://doi.org/10.1172/JCI45563.eng
dcterms.referencesZhai Y-L, Zhu L, Shi S-F, Liu L-J, Lv J-C, Zhang H. Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy. Medicine 2016;95:e3099. https://doi.org/10.1097/MD.0000000000003099.eng
dcterms.referencesYu X-Q, Li M, Zhang H, Low H-Q, Wei X, Wang J-Q, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 2012;44:178–82. https://doi.org/10.1038/ng.1047.eng
dcterms.referencesKiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014;46:1187–96. https://doi.org/10.1038/ng.3118.eng
dcterms.referencesMaillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, et al. Current Understanding of the Role of Complement in IgA Nephropathy. Journal of the American Society of Nephrology 2015;26:1503–12. https://doi.org/10.1681/ASN.2014101000.eng
dcterms.referencesGharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321–7. https://doi.org/10.1038/ng.787.eng
dcterms.referencesZhu L, Zhai Y-L, Wang F-M, Hou P, Lv J-C, Xu D-M, et al. Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. Journal of the American Society of Nephrology 2015;26:1195–204. https://doi.org/10.1681/ASN.2014010096.eng
dcterms.referencesIbels LS, Györy AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore). 1994 Mar;73(2):79-102. PMID: 8152367.eng
dcterms.referencesWyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S, Holland NH, et al. IgA nephropathy: Long-term prognosis for pediatric patients. The Journal of Pediatrics 1995;127:913–9. https://doi.org/10.1016/S0022-3476(95)70027-7.eng
dcterms.referencesRadford MG, Donadio JV, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. Journal of the American Society of Nephrology 1997;8:199–207. https://doi.org/10.1681/ASN.V82199.eng
dcterms.referencesFeehally J, Floege J, Tonelli M, et al. Comprehensive Clinical Nephrology. 6th ed.: Elsevier; 2019. p. 275.eng
dcterms.referencesKim J-K, Kim JH, Lee SC, Kang EW, Chang TI, Moon SJ, et al. Clinical Features and Outcomes of IgA Nephropathy with Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology 2012;7:427–36. https://doi.org/10.2215/CJN.04820511.eng
dcterms.referencesLai KN, Lai FM-M, Chan KW, Ho CP, Leung ACT, Vallance-Owen J. An Overlapping Syndrome of IgA Nephropathy and Lipoid Nephrosis. American Journal of Clinical Pathology 1986;86:716–23. https://doi.org/10.1093/ajcp/86.6.716.eng
dcterms.referencesHerlitz LC, Bomback AS, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. IgA Nephropathy with Minimal Change Disease. Clinical Journal of the American Society of Nephrology 2014;9:1033–9. https://doi.org/10.2215/CJN.11951113.eng
dcterms.referencesAbuelo JG, Esparza AR, Matarese RA, Endreny RG, Carvalho JS, Allegra SR. Crescentic IgA Nephropathy: Medicine 1984;63:396. https://doi.org/10.1097/00005792-198411000-00005.eng
dcterms.referencesGutiérrez E, González E, Hernández E, Morales E, Martínez MA, Usera G, Praga M. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol. 2007 Jan;2(1):51-7. https://doi.org/10.2215/CJN.02670706.eng
dcterms.referencesA Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney International 2009;76:534–45. https://doi.org/10.1038/ki.2009.243.eng
dcterms.referencesRoberts ISD. Oxford classification of immunoglobulin A nephropathy: an update. Current Opinion in Nephrology and Hypertension 2013;22:281–6. https://doi.org/10.1097/MNH.0b013e32835fe65c.eng
dcterms.referencesCoppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Terence Cook H, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney International 2010;77:921–7. https://doi.org/10.1038/ki.2010.43.eng
dcterms.referencesBarbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts ISD, Feehally J, et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney International 2016;89:167–75. https://doi.org/10.1038/ki.2015.322.eng
dcterms.referencesCoppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney International 2014;86:828–36. https://doi.org/10.1038/ki.2014.63.eng
dcterms.referencesTrimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney International 2017;91:1014–21. https://doi.org/10.1016/j.kint.2017.02.003.eng
dcterms.referencesHassler JR. IgA nephropathy: A brief review. Seminars in Diagnostic Pathology 2020;37:143–7. https://doi.org/10.1053/j.semdp.2020.03.001.eng
dcterms.referencesMathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh K-H, et al. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med 2024;390:20–31. https://doi.org/10.1056/NEJMoa2305635.eng
dcterms.referencesHeerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. The Lancet 2023;401:1584–94. https://doi.org/10.1016/S0140-6736(23)00569-X.eng
dcterms.referencesLafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. The Lancet 2023;402:859–70. https://doi.org/10.1016/S0140-6736(23)01554-4.eng
dcterms.referencesLv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA 2022;327:1888. https://doi.org/10.1001/jama.2022.5368.eng
dcterms.referencesHou FF, Xie D, Wang J, Xu X, Yang X, Ai J, et al. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. JAMA Netw Open 2023;6:e2254054. https://doi.org/10.1001/jamanetworkopen.2022.54054.eng
dcterms.referencesMiyabe Y, Karasawa K, Akiyama K, Ogura S, Takabe T, Sugiura N, et al. Grading system utilising the total score of Oxford classification for predicting renal prognosis in IgA nephropathy. Sci Rep 2021;11:3584. https://doi.org/10.1038/s41598-021-82967-x.eng
dcterms.referencesChen C-H, Wu M-J, Tsai S-F. Validating the association of Oxford classification and renal function deterioration among Taiwanese individuals with Immunoglobulin A nephropathy. Sci Rep 2023;13:21904. https://doi.org/10.1038/s41598-023-49331-7.eng
dcterms.referencesMoriyama T, Karasawa K, Miyabe Y, Akiyama K, Ogura S, Takabe T, et al. Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors. Sci Rep 2020;10:11151. https://doi.org/10.1038/s41598-020-68087-y.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersion
sb.programaEspecialización en Nefrologíaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
Miniatura
Nombre:
PDF_Resumen.pdf
Tamaño:
261.73 KB
Formato:
Adobe Portable Document Format
Descargar
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
905.71 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.93 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca